Share This Article:

Renal effects of vasodilators in acute heart failure

Full-Text HTML XML Download Download as PDF (Size:274KB) PP. 8-17
DOI: 10.4236/wjcd.2013.32A002    3,120 Downloads   5,957 Views   Citations

ABSTRACT

Vasodilator therapy is common in acute heart failure (AHF) patients, although evidence for morbidity and mortality benefits is limited for many of these drugs. AHF is frequently accompanied by renal dysfunction, which is a strong, independent predictor for poor prognosis. Several hemodynamic and neurohormonal effects of vasodilators—including preload and afterload reduction, activation or inhibition of neurohormonal and inflammatory cascades—have the potential to modulate cardiorenal interaction and impact renal function. However, the effect of vasodilators on renal function in acute heart failure is often poorly described. In this review, we provide an overview of the known cardiorenal effects of traditional and novel vasodilators in patients with acute heart failure.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Valente, M. and Voors, A. (2013) Renal effects of vasodilators in acute heart failure. World Journal of Cardiovascular Diseases, 3, 8-17. doi: 10.4236/wjcd.2013.32A002.

References

[1] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., et al. (2010) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 14, 803-869. doi:10.1093/eurjhf/hfs105
[2] Adams Jr., K.F., Fonarow, G.C., Emerman, C.L., LeJemtel, T.H., Costanzo, M.R., Abraham, W.T., et al. (2005) Characteristics and outcomes of patients hospitalized for heart failure in the united states: Rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). American Heart Journal, 149, 209-216. doi:10.1016/j.ahj.2004.08.005
[3] McMurray, J.J., Teerlink, J.R., Cotter, G., Bourge, R.C., Cleland, J.G., Jondeau, G., et al. (2007) Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomized controlled trials. Journal of the American Medical Association, 298, 2009-2019. doi:10.1001/jama.298.17.2009
[4] Damman, K., Jaarsma, T., Voors, A.A., Navis, G., Hillege, H.L., van Veldhuisen, D.J., et al. (2009) Both inand out-hospital worsening of renal function predict outcome in patients with heart failure: Results from the coordinating study evaluating outcome of advising and counseling in heart failure (COACH). European Journal of Heart Failure, 11, 847-854. doi:10.1093/eurjhf/hfp108
[5] Smilde, T.D., van Veldhuisen, D.J., Navis, G., Voors, A.A. and Hillege, H.L. (2006) Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation, 114, 1572-1580. doi:10.1161/CIRCULATIONAHA.105.610642
[6] Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro 3rd, A.F., Feldman, H.I., et al. (2009) A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150, 604-612. doi:10.7326/0003-4819-150-9-200905050-00006
[7] Lassus, J., Harjola, V.P., Sund, R., Siirila-Waris, K., Melin, J., Peuhkurinen, K., et al. (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. European Heart Journal, 28, 1841-1847. doi:10.1093/eurheartj/ehl507
[8] Shenkman, H.J., Za-reba, W. and Bisognano, J.D. (2007) Comparison of prognostic significance of amino-terminal pro-brain na-triuretic peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure. American Journal of Cardiology, 99, 1143-1145. doi:10.1016/j.amjcard.2006.11.050
[9] Filippatos, G., Rossi, J., Lloyd-Jones, D.M., Stough, W.G., Ouyang, J., Shin, D.D., et al. (2007) Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: Insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) study. Journal of Cardiac Failure, 13, 360-364. doi:10.1016/j.cardfail.2007.02.005
[10] Valente, M.A., Damman, K., Dunselman, P.H., Hillege, H.L. and Voors, A.A. (2012) Urinary proteins in heart failure. Progress in Cardiovascular Diseases, 55, 44-55. doi:10.1016/j.pcad.2012.04.009
[11] Campbell, C.Y., Clarke, W., Park, H., Haq, N., Barone, B.B. and Brotman, D.J. (2009) Usefulness of cystatin C and prognosis fol-lowing admission for acute heart failure. American Journal of Cardiology, 104, 389-392. doi:10.1016/j.amjcard.2009.03.059
[12] Damman, K., Van Veldhuisen, D.J., Navis, G., Vaidya, V.S., Smilde, T.D., Westenbrink, B.D., et al. (2010) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart, 96, 1297-1302. doi:10.1136/hrt.2010.194878
[13] Ronco, C., Cicoira, M. and McCullough, P.A. (2012) Cardiorenal syndrome type 1: Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. American College of Cardiology Foundation, 60, 1031-1042. doi:10.1016/j.jacc.2012.01.077
[14] Damman, K., Navis, G., Voors, A.A., Asselbergs, F.W., Smilde, T.D., Cleland, J.G., et al. (2007) Worsening renal function and prognosis in heart failure: Systematic review and meta-analysis. Journal of Cardiac Failure, 13, 599608. doi:10.1016/j.cardfail.2007.04.008
[15] Felker, G.M. and Mentz, R.J. (2012) Diuretics and ultrafiltration in acute decompensated heart failure. Journal of the American College of Cardiology, 59, 2145-2153. doi:10.1016/j.jacc.2011.10.910
[16] Voors, A.A., Dittrich, H.C., Massie, B.M., DeLucca, P., Mansoor, G.A., Metra, M., et al. (2011) Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: Results from PROTECT (placebo-controlled randomized study of the selective adenosine A1 receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function). Journal of the American College of Cardiology, 57, 18991907. doi:10.1016/j.jacc.2010.11.057
[17] Metra, M., Nodari, S., Parrinello, G., Bordonali, T., Bugatti, S., Danesi, R., et al. (2008) Worsening renal function in patients hospita-lised for acute heart failure: Clinical implications and prognostic significance. European Journal of Heart Failure, 10, 188-195. doi:10.1016/j.ejheart.2008.01.011
[18] Ronco, C., McCullough, P.A., Anker, S.D., Anand, I., Aspromonte, N., Bagshaw, S.M., et al. (2010) Cardiorenal syndromes: An executive summary from the consensus conference of the acute dialysis quality initiative (ADQI). Contributions to Nephrology, 165, 54-67. doi:10.1159/000313745
[19] Damman, K., Voors, A.A., Hillege, H.L., Navis, G., Lechat, P., van Veldhuisen, D.J., et al. (2010) Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. European Journal of Heart Failure, 12, 974-982. doi:10.1093/eurjhf/hfq118
[20] Damman, K., van Deursen, V.M., Navis, G., Voors, A.A., van Veldhuisen, D.J. and Hillege, H.L. (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. Journal of the American College of Cardiology, 53, 582-588. doi:10.1016/j.jacc.2008.08.080
[21] Damman, K., Navis, G., Smilde, T.D., Voors, A.A., van der Bij, W., van Veldhuisen, D.J., et al. (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. European Journal of Heart Failure, 9, 872-878. doi:10.1016/j.ejheart.2007.05.010
[22] Mullens, W., Abrahams, Z., Skouri, H.N., Francis, G.S., Taylor, D.O., Starling, R.C., et al. (2008) Elevated intra-abdominal pressure in acute decompensated heart failure: A potential contributor to worsening renal function? Journal of the American College of Cardiology, 51, 300-306. doi:10.1016/j.jacc.2007.09.043
[23] Damman, K., Voors, A.A., Navis, G., van Veldhuisen, D.J. and Hillege, H.L. (2011) The cardiorenal syndrome in heart failure. Progress in Cardiovascular Diseases, 54, 144-153. doi:10.1016/j.pcad.2011.01.003
[24] Weatherley, B.D., Cotter, G., Dittrich, H.C., DeLucca, P., Mansoor, G.A., Bloomfield, D.M., et al. (2010) Design and rationale of the PROTECT study: A placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Journal of Cardiac Failure, 16, 25-35. doi:10.1016/j.cardfail.2009.10.025
[25] Elkayam, U., Bitar, F., Akhter, M.W., Khan, S., Patrus, S. and Derakhshani, M. (2004) Intravenous nitroglycerin in the treatment of decompensated heart failure: Potential benefits and limitations. Journal of Cardiovascular Pharmacology and Therapeutics, 9, 227-241. doi:10.1177/107424840400900403
[26] Cotter, G., Metzkor, E., Kaluski, E., Faigenberg, Z., Miller, R., Simovitz, A., et al. (1998) Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet, 351, 389-393. doi:10.1016/S0140-6736(97)08417-1
[27] Sharon, A., Shpirer, I., Kaluski, E., Moshkovitz, Y., Milovanov, O., Polak, R., et al. (2000) High-dose intravenous isosorbide-dinitrate is safer and better than biPAP ventilation combined with conventional treatment for severe pulmonary edema. Journal of the American College of Cardiology, 36, 832-937. doi:10.1016/S0735-1097(00)00785-3
[28] Mullens, W., Abrahams, Z., Francis, G.S., Skouri, H.N., Starling, R.C., Young, J.B., et al. (2008) Sodium nitroprusside for advanced low-output heart failure. Journal of the American College of Cardiology, 52, 200-207. doi:10.1016/j.jacc.2008.02.083
[29] Bayram, M., De Luca, L., Massie, M.B. and Gheorghiade, M. (2005) Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. American Journal of Cardiology, 96, 47G-58G. doi:10.1016/j.amjcard.2005.07.021
[30] Packer, M., Carver, J.R., Rodeheffer, R.J., Ivanhoe, R.J., DiBianco, R., Zeldis, S.M., et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. The New England Journal of Medicine, 325, 1468-1475. doi:10.1056/NEJM199111213252103
[31] Stroshane, R.M., Koss, R.F., Biddlecome, C.E., Luczkowec, C. and Edelson, J. (1984) Oral and intravenous pharmacokinetics of milrinone in human volunteers. Journal of Pharmaceutical Sciences, 73, 1438-1441. doi:10.1002/jps.2600731029
[32] Klein, L., Massie, B.M., Leimberger, J.D., O’Connor, C.M., Pina, I.L., Adams Jr., K.F., et al. (2008) Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: Results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circulation: Heart Failure, 1, 25-33. doi:10.1161/CIRCHEARTFAILURE.107.746933
[33] Wei, C.M., Lerman, A., Rodeheffer, R.J., McGregor, C.G., Brandt, R.R., Wright, S., et al. (1994) Endothelin in human congestive heart failure. Circulation, 89, 15801586. doi:10.1161/01.CIR.89.4.1580
[34] Modesti, P.A., Cecioni, I., Costoli, A., Poggesi, L., Galanti, G. and Serneri, G.G. (2000) Renal endothelin in heart failure and its relation to sodium excretion. American Heart Journal, 140, 617-622. doi:10.1067/mhj.2000.109917
[35] Kaluski, E., Kobrin, I., Zimlichman, R., Marmor, A., Krakov, O., Milo, O., et al. (2003) RITZ-5: Randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study. Journal of the American College of Cardiology, 41, 204-210. doi:10.1016/S0735-1097(02)02708-0
[36] Torre-Amione, G., Young, J.B., Colucci, W.S., Lewis, B.S., Pratt, C., Cotter, G., et al. (2003) Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology, 42, 140-147. doi:10.1016/S0735-1097(03)00556-4
[37] Teerlink, J.R., McMurray, J.J., Bourge, R.C., Cleland, J.G., Cotter, G., Jondeau, G., et al. (2005) Tezosentan in patients with acute heart failure: Design of the value of endothelin receptor inhibition with tezosentan in acute heart failure study (VERITAS). American Heart Journal, 150, 46-53. doi:10.1016/j.ahj.2005.04.035
[38] Neuhofer, W. and Pittrow, D. (2006) Role of endothelin and endothelin receptor antagonists in renal disease. European Journal of Clinical Investigation, 36, 78-88. doi:10.1111/j.1365-2362.2006.01689.x
[39] Colucci, W.S., Elkayam, U., Horton, D.P., Abraham, W.T., Bourge, R.C., Johnson, A.D., et al. (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group. The New England Journal of Medicine, 343, 246253. doi:10.1056/NEJM200007273430403
[40] Mills, R.M., LeJemtel, T.H., Horton, D.P., Liang, C., Lang, R., Silver, M.A., et al. (1999) Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor study group. Journal of the American College of Cardiology, 34, 155-162. doi:10.1016/S0735-1097(99)00184-9
[41] Mitrovic, V., Seferovic, P.M., Simeunovic, D., Ristic, A.D., Miric, M., Moiseyev, V.S., et al. (2006) Haemodynamic and clinical effects of ularitide in decompensated heart failure. European Heart Journal, 27, 28232832. doi:10.1093/eurheartj/ehl337
[42] McKie, P.M., Sangaralingham, S.J. and Burnett Jr., J.C. (2010) CD-NP: An innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Current Heart Failure Reports, 7,93-99. doi:10.1007/s11897-010-0016-6
[43] Mitrovic, V., Her-nandez, A.F., Meyer, M. and Gheorghiade, M. (2009) Role of guanylate cyclase modulators in decompensated heart failure. Heart Failure Reviews, 14, 309-319. doi:10.1007/s10741-009-9149-7
[44] Sackner-Bernstein, J.D., Skopicki, H.A. and Aaronson, K.D. (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation, 111, 1487-1491. doi:10.1161/01.CIR.0000159340.93220.E4
[45] Sackner-Bernstein, J.D., Kowalski, M., Fox, M. And Aaronson, K. (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA, 293, 1900-1905. doi:10.1001/jama.293.15.1900
[46] Arora, R.R., Venkatesh, P.K. and Molnar, J. (2006) Short and long-term mortality with nesiritide. American Heart Journal, 152, 1084-1090. doi:10.1016/j.ahj.2006.07.002
[47] O’Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., et al. (2011) Effect of nesiritide in patients with acute decompensated heart failure. The New England Journal of Medicine, 365, 32-43. doi:10.1056/NEJMoa1100171
[48] Mitrovic, V., Luss, H., Nitsche, K., Forssmann, K., Maronde, E., Fricke, K., et al. (2005) Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: A double-blind, placebo-controlled, ascending-dose trial. American Heart Journal, 150, 1239. doi:10.1016/j.ahj.2005.01.022
[49] Luss, H., Mitrovic, V., Seferovic, P.M., Simeunovic, D., Ristic, A.D., Moiseyev, V.S., et al. (2008) Renal effects of ularitide in patients with decompensated heart failure. American Heart Journal, 155, 1012.e1-1012.e8.
[50] Martin, F.L., Sangaralingham, S.J., Huntley, B.K., McKie, P.M., Ichiki, T., Chen, H.H., et al. (2012) CD-NP: A novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One, 7, e52422. doi:10.1371/journal.pone.0052422
[51] Rose, R.A. (2010) CD-NP, a chimeric natriuretic peptide for the treatment of heart failure. Current Opinion in Investigational Drugs, 11, 349-356.
[52] Lee, C.Y., Chen, H.H., Lisy, O., Swan, S., Cannon, C., Lieu, H.D., et al. (2009) Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. The Journal of Clinical Pharmacology, 49, 668-673. doi:10.1177/0091270009336233
[53] Fischer, D., Rossa, S., Landmesser, U., Spiekermann, S., Engberding, N., Hornig, B., et al. (2005) Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. European Heart Journal, 26, 65-69. doi:10.1093/eurheartj/ehi001
[54] Surmeli, N. and Marletta, M.A. (2012) Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat. ChemBioChem, 13, 977-981. doi:10.1002/cbic.201100809
[55] Erdmann, E., Semigran, M.J., Nieminen, M.S., Gheorghiade, M., Agrawal, R., Mitrovic, V., et al. (2013) Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. European Heart Journal, 34, 57-67. doi:10.1093/eurheartj/ehs196
[56] Lapp, H., Mitrovic, V., Franz, N., Heuer, H., Buerke, M., Wolfertz, J., et al. (2009) Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation, 119, 2781-1788. doi:10.1161/CIRCULATIONAHA.108.800292
[57] Gheorghiade, M., Greene, S.J., Filippatos, G., Erdmann, E., Ferrari, R., Levy, P.D., et al. (2012) Cinaciguat, a soluble guanylate cyclase activator: Results from the randomized, controlled, phase IIb COMPOSE programmme in acute heart failure syndromes. European Journal of Heart Failure, 14, 1056-1066. doi:10.1093/eurjhf/hfs093
[58] Oghlakian, G. and Klapholz, M. (2009) Vasopressin and vasopressin receptor antagonists in heart failure. Cardiology in Review, 17, 10-15. doi:10.1097/CRD.0b013e318190e72c
[59] Gheorghiade, M., Gattis, W.A., O’Connor, C.M., Adams Jr., K.F., Elkayam, U., Barbagelata, A., et al. (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA, 291, 1963-1971. doi:10.1001/jama.291.16.1963
[60] Gheorghiade, M., Gattis, W.A., Barbagelata, A., Adams Jr., KF, Elkayam, U., Orlandi, C., et al. (2003) Rationale and study design for a multicenter, randomized, doubleblind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal, 145, S51-S54. doi:10.1067/mhj.2003.154
[61] Gheorghiade, M., Niazi, I., Ouyang, J., Czerwiec, F., Kambayashi, J., Zampino, M., et al. (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation, 107, 2690-2696. doi:10.1161/01.CIR.0000070422.41439.04
[62] Konstam, M.A., Gheorghiade, M., Burnett Jr., J.C., Grinfeld, L., Maggioni, A.P., Swedberg, K., et al. (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA, 297, 1319-1331. doi:10.1001/jama.297.12.1319
[63] Gheorghiade, M., Konstam, M.A., Burnett Jr., J.C., Grinfeld, L., Maggioni, A.P., Swedberg, K., et al. (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials. JAMA, 297, 1332-1343. doi:10.1001/jama.297.12.1332
[64] Udelson, J.E., Smith, W.B., Hendrix, G.H., Painchaud, C.A., Ghazzi, M., Thomas, I., et al. (2001) Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation, 104, 2417-2423. doi:10.1161/hc4501.099313
[65] Burnier, M., Fricker, A.F., Hayoz, D., Nussberger, J. and Brunner, H.R. (1999) Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. European Journal of Clinical Pharmacology, 55, 633-637. doi:10.1007/s002280050685
[66] Mondritzki, T., Kolkhof, P., Sabbah, H.N., Gheorghiade, M., Furstner, C., Schmeck, C., et al. (2011) Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model. American Journal of Therapeutics, 18, 31-37. doi:10.1097/MJT.0b013e3181f890ad
[67] Goldsmith, S.R. (2012) Hyponatremia and outcomes in patients with heart failure. Heart, 98, 1761-1762. doi:10.1136/heartjnl-2012-302854
[68] Givertz, M.M., Massie, B.M., Fields, T.K., Pearson, L.L. and Dittrich H,C. (2007) CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. Journal of the American College of Cardiology, 50, 1551-1560. doi:10.1016/j.jacc.2007.07.019
[69] Gottlieb, S.S., Brater, D.C., Thomas, I., Havranek, E., Bourge, R., Goldman, S., et al. (2002) BG9719 (CVT124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation, 105, 1348-1353. doi:10.1161/hc1102.105264
[70] Massie, B.M., O’Connor, C.M., Metra, M., Ponikowski, P., Teerlink, J.R., Cotter, G., et al. (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. The New England Journal of Medicine, 363, 1419-1428. doi:10.1056/NEJMoa0912613
[71] Gottlieb, S.S., Ticho, B., Deykin, A., Abraham, W.T., Denofrio, D., Russell, S.D., et al. (2011) Effects of BG9928, an adenosine A(1) receptor antagonist, in patients with congestive heart failure. The Journal of Clinical Pharmacology, 51, 899-907. doi:10.1177/0091270010375957
[72] Greenberg, B., Thomas, I., Banish, D., Goldman, S., Havranek, E., Massie, B.M., et al. (2007) Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: Results of a placebo-controlled, dose-escalation study. Journal of the American College of Cardiology, 50, 600-606. doi:10.1016/j.jacc.2007.03.059
[73] Sorsa, T., Heikkinen, S., Abbott, M.B., Abusamhadneh, E., Laakso, T., Tilgmann, C., et al. (2001) Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. Journal of Biological Chemistry, 276, 9337-9343. doi:10.1074/jbc.M007484200
[74] Janssen, P.M., Datz, N., Zeitz, O. and Hasenfuss, G. (2000) Levosimendan improves diastolic and systolic function in failing human myocardium. European Journal of Pharmacology, 404, 191-199. doi:10.1016/S0014-2999(00)00609-9
[75] Hasenfuss, G., Pieske, B., Castell, M., Kretschmann, B., Maier, L.S. and Just. H. (1998) Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 98, 2141-2147. doi:10.1161/01.CIR.98.20.2141
[76] Krassoi, I., Pataricza, J., Kun, A. and Papp, J.G. (2000) Calcium-dependent vasorelaxant capacity of levosimendan in porcine and human epicardial coronary artery preparations. Cardiovascular Drugs and Therapy, 14, 691-693. doi:10.1023/A:1007883402379
[77] Pataricza, J., Hohn, J., Petri, A., Balogh, A. and Papp, J.G. (2000) Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. Pharmaceutical & Medicinal Chemistry, 52, 213-217. doi:10.1211/0022357001773715
[78] Packer, M. (2005) REVIVE-II: Multicenter placebocontrolled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation, 112, 3362-3364.
[79] Mebazaa, A., Nieminen, M.S., Packer, M., Cohen-Solal, A., Kleber, F.X., Pocock, S.J., et al. (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. JAMA, 297, 1883-1891. doi:10.1001/jama.297.17.1883
[80] Moiseyev, V.S., Poder, P., Andrejevs, N., Ruda, M.Y., Golikov, A.P., Lazebnik, L.B., et al. (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). European Heart Journal, 23, 1422-1432. doi:10.1053/euhj.2001.3158
[81] Follath, F., Cleland, J.G., Just, H., Papp, J.G., Scholz, H., Peuhkurinen, K., et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet, 360, 196-202. doi:10.1016/S0140-6736(02)09455-2
[82] Yilmaz, M.B., Yalta, K., Yontar, C., Karadas, F., Erdem, A., Turgut, O.O., et al. (2007) Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine. Cardiovascular Drugs and Therapy, 21, 431-435. doi:10.1007/s10557-007-6066-7
[83] Zemljic, G., Bunc, M., Yazdanbakhsh, A.P. and Vrtovec, B. (2007) Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. Journal of Cardiac Failure, 13, 417-421. doi:10.1016/j.cardfail.2007.03.005
[84] Hou, Z.Q., Sun, Z.X., Su, C.Y., Tan, H., Zhong, X., Hu, B., et al. (2012) Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovascular Therapeutics, Accepted article. doi:10.1111/cdr.12001
[85] Parissis, J.T., Farmakis, D. and Nieminen, M. (2007) Classical inotropes and new cardiac enhancers. Heart Fail Reviews, 12, 149-156. doi:10.1007/s10741-007-9014-5
[86] Teichman, S.L., Unemori, E., Dschietzig, T., Conrad, K., Voors, A.A., Teerlink, J.R., et al. (2009) Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Reviews, 14, 321-329. doi:10.1007/s10741-008-9129-3
[87] Dschietzig, T., Teichman, S., Unemori, E., Wood, S., Boehmer, J., Richter, C., et al. (2009) Intravenous recombinant human relaxin in compensated heart failure: A safety, tolerability, and pharmacodynamic trial. Journal of Cardiac Failure, 15, 182-190. doi:10.1016/j.cardfail.2009.01.008
[88] Teichman, S.L., Unemori, E., Teerlink, J.R., Cotter, G. and Metra, M. (2010) Relaxin: Review of biology and potential role in treating heart failure. Current Heart Failure Reports, 7, 75-82. doi:10.1007/s11897-010-0010-z
[89] Teerlink, J.R., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., et al. (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet, 381, 29-39. doi:10.1016/S0140-6736(12)61855-8
[90] Metra, M., Cotter, G., Davison, B.A., Felker, G.M., Filippatos, G., Greenberg, B.H., et al. (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: Correlation with outcomes. American College of Cardiology Foundation, 61, 196-206.
[91] Damman, K. and Voors, A.A. (2007) Levosimendan improves renal function in acute decompensated heart failure: Cause and clinical application. editorial to: “Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine by yilmaz et al.” Cardiovascular Drugs and Therapy, 21, 403-404. doi:10.1007/s10557-007-6070-y

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.